JP2010522772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522772A5 JP2010522772A5 JP2010501268A JP2010501268A JP2010522772A5 JP 2010522772 A5 JP2010522772 A5 JP 2010522772A5 JP 2010501268 A JP2010501268 A JP 2010501268A JP 2010501268 A JP2010501268 A JP 2010501268A JP 2010522772 A5 JP2010522772 A5 JP 2010522772A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- antibody
- malignant
- cells
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003211 malignant effect Effects 0.000 claims description 66
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 57
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 17
- 230000002489 hematologic effect Effects 0.000 claims description 17
- 210000003289 regulatory T cell Anatomy 0.000 claims description 14
- 206010066476 Haematological malignancy Diseases 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000004083 survival effect Effects 0.000 claims description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 8
- 230000036210 malignancy Effects 0.000 claims description 8
- 210000001616 monocyte Anatomy 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 206010062767 Hypophysitis Diseases 0.000 claims description 6
- 210000004100 adrenal gland Anatomy 0.000 claims description 6
- 210000000013 bile duct Anatomy 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 210000003679 cervix uteri Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 6
- 210000003238 esophagus Anatomy 0.000 claims description 6
- 210000001508 eye Anatomy 0.000 claims description 6
- 229950001109 galiximab Drugs 0.000 claims description 6
- 210000000232 gallbladder Anatomy 0.000 claims description 6
- 210000003026 hypopharynx Anatomy 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 210000005001 male reproductive tract Anatomy 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 210000003300 oropharynx Anatomy 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 210000003635 pituitary gland Anatomy 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 210000000664 rectum Anatomy 0.000 claims description 6
- 210000001625 seminal vesicle Anatomy 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 claims description 6
- 210000000813 small intestine Anatomy 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 210000001550 testis Anatomy 0.000 claims description 6
- 210000001685 thyroid gland Anatomy 0.000 claims description 6
- 210000003932 urinary bladder Anatomy 0.000 claims description 6
- 210000001635 urinary tract Anatomy 0.000 claims description 6
- 210000003741 urothelium Anatomy 0.000 claims description 6
- 210000004291 uterus Anatomy 0.000 claims description 6
- 201000010653 vesiculitis Diseases 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 102000003814 Interleukin-10 Human genes 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 5
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102000004388 Interleukin-4 Human genes 0.000 claims description 5
- 108090000978 Interleukin-4 Proteins 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229960003130 interferon gamma Drugs 0.000 claims description 5
- 229940076144 interleukin-10 Drugs 0.000 claims description 5
- 229940117681 interleukin-12 Drugs 0.000 claims description 5
- 229940028885 interleukin-4 Drugs 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 108010029697 CD40 Ligand Proteins 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100032937 CD40 ligand Human genes 0.000 claims description 4
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 230000003915 cell function Effects 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 229940100601 interleukin-6 Drugs 0.000 claims description 4
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 3
- 102000006382 Ribonucleases Human genes 0.000 claims description 3
- 108010083644 Ribonucleases Proteins 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 230000001028 anti-proliverative effect Effects 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 230000001461 cytolytic effect Effects 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 claims description 3
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000002619 cytotoxin Substances 0.000 claims description 3
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 239000003207 proteasome inhibitor Substances 0.000 claims description 3
- -1 radioisotope Substances 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 19
- 210000004408 hybridoma Anatomy 0.000 claims 5
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 230000002584 immunomodulator Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 230000003171 anti-complementary effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 210000005002 female reproductive tract Anatomy 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 229940096397 interleukin-8 Drugs 0.000 claims 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 118
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 5
- 210000003372 endocrine gland Anatomy 0.000 description 5
- 208000022006 malignant tumor of meninges Diseases 0.000 description 5
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90864507P | 2007-03-28 | 2007-03-28 | |
| PCT/US2008/058744 WO2008119071A1 (en) | 2007-03-28 | 2008-03-28 | Modulation of tumor microenvironment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522772A JP2010522772A (ja) | 2010-07-08 |
| JP2010522772A5 true JP2010522772A5 (enExample) | 2011-05-06 |
Family
ID=39485176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501268A Pending JP2010522772A (ja) | 2007-03-28 | 2008-03-28 | 腫瘍微小環境の調整 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100203010A1 (enExample) |
| EP (1) | EP2139923A1 (enExample) |
| JP (1) | JP2010522772A (enExample) |
| CN (1) | CN101679522A (enExample) |
| AU (1) | AU2008230724A1 (enExample) |
| BR (1) | BRPI0809386A2 (enExample) |
| CA (1) | CA2682027A1 (enExample) |
| WO (1) | WO2008119071A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6014799B2 (ja) * | 2010-07-20 | 2016-10-26 | Ｌｉｎｆｏｐｓ有限会社 | 解析によるミクロな腫瘍免疫挙動の顕微鏡的把握方法 |
| EP3147297B1 (en) * | 2011-03-31 | 2018-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
| US9567642B2 (en) | 2012-02-02 | 2017-02-14 | Massachusetts Institute Of Technology | Methods and products related to targeted cancer therapy |
| US8961957B2 (en) | 2012-06-27 | 2015-02-24 | Hasumi International Research Foundation | Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10 |
| US9907819B2 (en) | 2012-06-27 | 2018-03-06 | Kenichiro Hasumi | Therapy and methods of introducing immature dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors |
| US9945870B2 (en) | 2013-05-17 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| WO2015077532A1 (en) * | 2013-11-21 | 2015-05-28 | Hasumi International Research Foundation | Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti-tnf antibody for treatment of tumors |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CA2942245C (en) * | 2014-03-12 | 2021-11-02 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| EP3215163B1 (en) * | 2014-11-06 | 2021-03-10 | Biothera, Inc. | Beta-glucan methods and compositions that affect the tumor microenvironment |
| US20160206717A1 (en) * | 2015-01-16 | 2016-07-21 | Batu Biologics, Inc. | Stimulation of immunity to endothelial cells, endothelial-like cells, and intratumor vascular channels derived from tumor tissue |
| JP2016155776A (ja) * | 2015-02-24 | 2016-09-01 | 学校法人兵庫医科大学 | 抗腫瘍効果増強剤および抗腫瘍剤 |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| KR20190139216A (ko) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11506915A (ja) * | 1995-06-07 | 1999-06-22 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Ｃｄ８０およびｃｄ８６発現細胞に対して特異的なイムノトキシン |
| US7175847B1 (en) * | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| WO2001089567A1 (en) * | 2000-05-22 | 2001-11-29 | Idec Pharmaceuticals Corporation | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
| US20070065436A1 (en) * | 2001-01-31 | 2007-03-22 | Biogen Idec Inc. | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
-
2008
- 2008-03-28 WO PCT/US2008/058744 patent/WO2008119071A1/en not_active Ceased
- 2008-03-28 CA CA002682027A patent/CA2682027A1/en not_active Abandoned
- 2008-03-28 EP EP08744673A patent/EP2139923A1/en not_active Withdrawn
- 2008-03-28 JP JP2010501268A patent/JP2010522772A/ja active Pending
- 2008-03-28 AU AU2008230724A patent/AU2008230724A1/en not_active Abandoned
- 2008-03-28 BR BRPI0809386-5A patent/BRPI0809386A2/pt not_active IP Right Cessation
- 2008-03-28 CN CN200880017793A patent/CN101679522A/zh active Pending
- 2008-03-28 US US12/593,231 patent/US20100203010A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522772A5 (enExample) | ||
| JP7258981B2 (ja) | 放射線療法と併用されるｐｄ－１およびｐｄ－ｌ１に対する拮抗薬を用いたがんの治療法 | |
| Li et al. | Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression | |
| TWI253934B (en) | Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplant | |
| Marabelle et al. | Intratumoral immunization: a new paradigm for cancer therapy | |
| KR102595561B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| Wu et al. | CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma | |
| EP3311841B1 (en) | Anticancer agent | |
| Yaddanapudi et al. | Cancer vaccines: Looking to the future | |
| Tai et al. | Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells | |
| CN108392633B (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| ES2460899T3 (es) | Inmunoterapia basada en células cancerosas alógenas | |
| JP2015534577A5 (enExample) | ||
| CN111989118A (zh) | 包含耗竭性抗cd4单克隆抗体的抗癌t细胞治疗剂辅助用组合物及其用途 | |
| JP2019536786A5 (enExample) | ||
| JP2015517511A5 (enExample) | ||
| KR20230147758A (ko) | 암 면역 아쥬반트 | |
| Li et al. | C-CAR039, a novel anti-CD20/CD19 bi-specific CAR T-cell therapy shows deep and durable clinical benefits in patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) in long term follow up | |
| Beyer et al. | Immunoregulatory T cells: role and potential as a target in malignancy | |
| JP7492752B2 (ja) | 免疫療法のためのアジュバントとしてのグアナベンズ | |
| JP2014510047A5 (enExample) | ||
| WO2017174649A1 (en) | Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof | |
| JP2021517588A5 (enExample) | ||
| WO2026096415A1 (en) | Ex vivo generated antigen-specific cd4+ t cells with enhanced self-renewal and cytotoxic activity for immunotherapy of cancer | |
| Dang et al. | Radiotherapy combined with cytokine-induced killer cell therapy for liver metastasis from rectal cancer: a case report |